Health Care [ 4/12 ] | Pharmaceuticals [ 21/74 ]
NASDAQ | Common Stock
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.
It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder.
The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | 6.60 Increased by +31.47% | 5.81 Increased by +13.58% |
| Nov 6, 24 | 6.61 Increased by +36.57% | 5.50 Increased by +20.18% |
| Jul 31, 24 | 5.30 Increased by +17.52% | 4.77 Increased by +11.11% |
| May 1, 24 | 2.68 Decreased by -32.15% | 4.18 Decreased by -35.89% |
| Feb 28, 24 | 5.02 Increased by +7.27 K% | 5.18 Decreased by -3.09% |
| Nov 8, 23 | 4.84 Decreased by -6.38% | 4.93 Decreased by -1.83% |
| Aug 9, 23 | 4.51 Increased by +4.88% | 4.43 Increased by +1.81% |
| May 10, 23 | 3.95 Increased by +5.90% | 4.24 Decreased by -6.84% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 1.09 B Increased by +7.53% | 191.12 M Increased by +102.98% | Increased by +17.56% Increased by +88.76% |
| Sep 30, 24 | 1.05 B Increased by +8.52% | 215.06 M Increased by +46.48% | Increased by +20.38% Increased by +34.98% |
| Jun 30, 24 | 1.02 B Increased by +6.95% | 168.57 M Increased by +61.40% | Increased by +16.46% Increased by +50.92% |
| Mar 31, 24 | 901.98 M Increased by +1.03% | -14.62 M Decreased by -121.06% | Decreased by -1.62% Decreased by -120.84% |
| Dec 31, 23 | 1.01 B Increased by +4.10% | 94.15 M Increased by +139.24% | Increased by +9.30% Increased by +137.70% |
| Sep 30, 23 | 972.14 M Increased by +3.35% | 146.82 M Increased by +958.45% | Increased by +15.10% Increased by +930.64% |
| Jun 30, 23 | 957.32 M Increased by +2.62% | 104.44 M Increased by +201.28% | Increased by +10.91% Increased by +193.59% |
| Mar 31, 23 | 892.81 M Increased by +9.72% | 69.42 M Increased by +1.10 K% | Increased by +7.78% Increased by +992.94% |